Objective: To confirm the pathologic status of lymph nodes based on the risk factors of endometrial cancer patients. Methods: The medical records of 468 patients were retrospectively reviewed. The study population included patients diagnosed with early-stage endometrial cancer between January 2006 and December 2018. Patients were categorized into pelvic lymph node dissection (PLND) and pelvic plus para-aortic lymph nodes dissection (PPALND) groups. Demographics, recurrence-free survival, and five-year survival rates were compared, and the clinical factors affecting survival were evaluated using univariate and multivariate analyses. Results: The median follow-up period was 55 months (range, 6-142 months). The mean age was higher in the PPALND group than in the PLND group (51.0 vs 54.5 years; P <0.001). The PPALND showed higher FIGO stage, lympho-vascular invasion, endocervical invasion, and FIGO grade (P=0.001) than the PLND group. When comparing the five-year recurrence and survival rates, the PPALND group showed higher rates than the PLND group. While comparing lymph node (LN) metastasis confirmed by pathology, the group with confirmed metastasis showed an increased number of high-risk patients. Additionally, there was a difference in almost all clinical factors. However, no difference was observed while comparing the pelvic LN metastasis, pelvic plus para-aortic LN metastasis, and isolated para-aortic LN metastasis groups. Conclusion: When treating patients with early-stage endometrial cancer, risk group evaluation is an important factor for determining LN dissection. Our study found no difference among LN metastasis regional differences.